AnaptysBio, Inc.
ANAB
$20.25
-$0.115-0.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.78% | -80.54% | 33.69% | 29.59% | -6.20% |
| Total Depreciation and Amortization | -0.83% | 0.83% | 0.84% | 0.17% | -1.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.59% | 9.78% | 10.70% | 31.31% | 18.84% |
| Change in Net Operating Assets | -1,298.17% | 103.58% | -6,191.67% | -87.06% | 217.85% |
| Cash from Operations | -276.11% | 83.95% | -560.77% | 52.68% | 42.76% |
| Capital Expenditure | -11.43% | 86.69% | -651.43% | -6.06% | -22.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 144.87% | 151.08% | -149.67% | 2,534.83% | -103.51% |
| Cash from Investing | 145.19% | 150.51% | -150.15% | 2,500.49% | -103.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 390.69% | -47.75% | -99.44% | 9,960.98% | 20.72% |
| Repurchase of Common Stock | -1,055.02% | -870.18% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 96.63% | -189.03% | 200.74% | -166.65% | 383.24% |
| Cash from Financing | -76.63% | -203.71% | -61.30% | 70.04% | 407.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.31% | 64.32% | -157.20% | 560.71% | 2.23% |